Rznomics, a company specializing in developing ribonucleic acid (RNA)-based gene therapies, said on the 22nd that it received preliminary listing approval from the Korea Exchange.
The listing underwriters are NH Investment & Securities and Samsung Securities, and the company aims to begin the full listing process and complete the listing within the year.
Founded in 2017, Rznomics is a corporations that develops innovative therapies for anticancer treatment and rare intractable diseases using its independently developed RNA editing and correction platform based on an RNA replacement enzyme.
Earlier, the company received an A grade from each of two specialized evaluation institutions designated by the Korea Exchange. In May last year, it was confirmed by the Ministry of Science and ICT and the Korea Institute of S&T Evaluation and Planning as the "No. 1 national strategic technology corporations," and in September it was designated as a "national strategic technology holding and management company."
Based on this, it plans to follow the super-gap technology special listing track. The industry projected that among the national strategic technology corporations managed by the Ministry of Science and ICT, it will become the first corporations to receive the super-gap special listing.
The company said it has multiple therapeutic R&D pipelines, including for intractable cancers such as hepatocellular carcinoma and glioblastoma, Alzheimer's dementia, hereditary retinitis pigmentosa, and rare neurological diseases. Its flagship anticancer gene therapy candidate, "RZ-001," received Fast Track and orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA).
In particular, in May, it signed a platform-based global licensing agreement with U.S. pharmaceutical company Eli Lilly and Company to develop RNA editing and correction therapies, highlighting its platform competitiveness.
Lee Sung-uk, CEO of Rznomics, said, "Rznomics is developing innovative therapies that go beyond existing limits based on the world's first RNA replacement enzyme platform," adding, "Through this KOSDAQ listing, we will open a new paradigm for next-generation RNA correction therapies on the global stage."